The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial
{{output}}
Background: The tumour microenvironment (TME) influences breast cancer progression and treatment response. We investigated whether TME composition predicts tamoxifen benefit in postmenopausal women with oestrogen receptor-positiv... ...
